Can dapagliflozin be started at eGFR below 25?

For the CKD indication, initiation requires eGFR ≥25. People already on it can continue as GFR falls below that. It is discontinued when dialysis starts because there's no evidence of benefit at that stage.

Does dapagliflozin cause weight loss?

Mild — typically 2-3 kg over months, from glucose and calorie loss in urine. Modest weight reduction, but combined with blood pressure (~4 mmHg) and albuminuria reduction, the overall cardiovascular-kidney benefit is large.

What do the KDIGO guidelines say about dapagliflozin in CKD?

KDIGO 2024 recommends SGLT2 inhibitors (dapagliflozin or empagliflozin) for adults with CKD and eGFR ≥20, regardless of diabetes status, and for all diabetic CKD patients (KDIGO 2022). The 2024 CKD guideline explicitly recommends starting an SGLT2 inhibitor in CKD with eGFR ≥20 and/or UACR ≥200 mg/g — dapagliflozin (start eGFR ≥25) and empagliflozin (start eGFR ≥20) are both options.

SGLT2 inhibitor

Dapagliflozin (Farxiga/Forxiga) and Kidneys

Brand names: Farxiga / Forxiga • Drug class: SGLT2 inhibitor

Dapagliflozin is the first SGLT2 inhibitor proven to protect kidneys in CKD with and without diabetes (DAPA-CKD trial, NEJM 2020) — a 39% reduction in kidney failure risk. It also treats heart failure and is taken as one tablet a day.

How it affects the kidneys

Dapagliflozin is licensed specifically for chronic kidney disease with albuminuria at eGFR ≥25. It slows eGFR decline, cuts albuminuria ~38%, and reduces the need for dialysis or transplant. It also reduces hospitalizations for heart failure — the leading complication of CKD.

Evidence at a glance

39% relative risk reduction in the primary composite (kidney failure, doubling of creatinine, kidney death)

DAPA-CKD, 2020

29% reduction in all-cause death in CKD patients

DAPA-CKD, 2020

Benefits consistent in diabetic and non-diabetic CKD

DAPA-CKD subgroup analysis, 2020

Renal dosing guidance

10 mg once daily. Initiate at eGFR ≥25 mL/min/1.73m² for the CKD indication. Continue when GFR falls while on therapy; discontinue at dialysis initiation. No dose adjustment for age or liver disease.

Check your kidney function